Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring <i>EGFR</i> mutation: an observational clinical study.

"Hisashi Tanaka: personal fees as honoraria from Ono Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim, and Pfizer; Yoshitaka Seki: personal fees as honoraria from AstraZeneca, Eli Lilly, MSD, Ono Pharmaceutical, Novartis, Taiho Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, Shionogi, Sanofi, Kyowa Kirin, Kyorin Pharmaceutical, and GSK; Kazuma Kishi: research funding and personal fees as honoraria from Boehringer Ingelheim; Yusuke Okuma: research funding and personal fees as honoraria from AstraZeneca and Chugai Pharmaceutical; research funding from AbbVie; and personal fees as honoraria from Eisai, Eli Lilly, MSD, Novartis, Ono Pharmaceutical, Takeda Pharmaceutical, and Taiho Pharmaceutical; Akira Togashi: employee of Boehringer Ingelheim; Nobuhiko Seki: research funding and personal fees as honoraria from Eli Lilly, Ono Pharmaceutical, Boehringer Ingelheim, Taiho Pharmaceutical, Chugai Pharmaceutical, Takeda Pharmaceutical, Nippon Kayaku, Pfizer, and Daiichi Sankyo; research funding from Eisai and Shionogi; and personal fees as honoraria from AstraZeneca, MSD, Bristol Myers Squibb, Novartis, and Kyowa Kirin. No potential conflicts of interest were disclosed by the other authors."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Boehringer Ingelheim."

"Trial registration: UMIN-CTR identifier (UMIN000024935, https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_his_list.cgi?recptno=R000028688"